Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
about
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responsesMedical management of Parkinson's diseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseNovel NMDA receptor modulators: an updateNMDA receptor modulators: an updated patent review (2013-2014)Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neuronsGlutamate receptor ion channels: structure, regulation, and functionUnprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseaseIFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy.Potential future neuroprotective therapies for neurodegenerative disorders and stroke.Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists.The effects of NMDA subunit composition on calcium influx and spike timing-dependent plasticity in striatal medium spiny neuronsStructural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.Neuroprotective effect of lovastatin by inhibiting NMDA receptor1 in 6-hydroxydopamine treated PC12 cellsCytoprotective effects of hydrogen sulfide-releasing N-methyl-D-aspartate receptor antagonists are mediated by intracellular sulfane sulfur.HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanismThe involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.Measurement of NMDA Receptor Antagonist, CPP, in Mouse Plasma and Brain Tissue Following Systematic Administration Using Ion-Pair LCMS/MSMechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulatorsSolid Microneedles for Transdermal Delivery of Amantadine Hydrochloride and Pramipexole Dihydrochloride.Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complicationsMolecular pharmacology of human NMDA receptorsDiscovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.Pain and motor complications in Parkinson's disease.A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia.Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.DNA microarray unravels rapid changes in transcriptome of MK-801 treated rat brain.NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus.Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptorsSigma receptors [σRs]: biology in normal and diseased statesDifferences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatumMolecular pathways and genetic aspects of Parkinson's disease: from bench to bedside.Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.Targets for neuroprotection in Parkinson's diseaseControl of NMDA receptor function by the NR2 subunit amino-terminal domainFunctional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy.
P2860
Q21560808-55D83E6B-F04F-4D3E-BA4C-C4273BC3C588Q24647827-02EE1ADB-6D79-40D1-819E-68E81C396F8EQ26747508-BE94257D-86C8-40CB-A1E1-97BF6EE2FCB1Q26825619-FBAEAB4F-18C3-4557-9BE7-B76DF7A16C99Q26849614-A7E4F816-4DDC-4E80-8C83-ACF63B841611Q26997407-C6474A3A-8F15-4D1F-9DDB-18CA7FB148A1Q27330088-06D664A0-8F1B-4FA8-B2E8-23882432C7DBQ28290774-7D2450F9-E29D-4F8B-940B-4E5308F97FE9Q28542729-520F4CA4-2B9D-458A-A371-1D8DCBC63E76Q33620624-041D0419-2B67-4870-A7C8-7F11B451FCCCQ33687436-6B3EB6BF-F32B-4C6A-97D8-77D55FA5B9B5Q33825775-230D0196-B89A-46C0-8ABE-9F553FEA6CF5Q34059951-9690F856-B88E-4DBC-9288-B0CDD1C3BE84Q34246880-E2D67115-F7F5-478E-BDE1-4E22BF39448DQ34360057-F672A173-BDEC-4284-B259-CEADBFC5A216Q34547840-9E8A9E56-02D7-467D-884F-8FE00C367E04Q34565353-B77D6E7A-44AC-4443-A726-4CC6A9FEE9F9Q35007551-2A2F7BB3-A85F-4ACC-9327-9A1994863415Q35029070-F32C1DAA-EE37-420B-B1A1-5C4E9E5ED95AQ35051381-613628CF-EE8C-4CAA-85CF-12C140BB6806Q35415834-008AB9DA-BA00-4551-9C31-C798DC6143E6Q35794829-8F013DA9-71FC-4C8A-A757-3C0B85DFEBCEQ35885603-1F115D58-7C9C-40E2-832C-2C69814FF0DFQ35911379-4E18985F-683C-484F-9D26-BEC1C1FA60DEQ36015381-B81DCE67-E2DD-4812-BFA3-66D3BA7E7619Q36020776-2C84C768-D86F-42F6-A09A-0B1E8F0FE305Q36105509-87A1B460-B395-4EB0-BF38-FDC434CA85CCQ36226497-753D7E74-ABBE-46CE-9C7E-EEC345972D8EQ36275333-4BBD824C-FB1E-483A-A80D-693592D859CFQ36276693-32147070-A11B-4AA2-9224-13B2CCEFB85BQ36310447-5D9743E9-E111-4F48-85DD-DDA0D079FCC9Q36339205-22276222-F686-4D3B-BA6B-B88609D00AE9Q36851341-6EF465ED-308F-49F2-A952-892EAB331FCAQ37000551-6ACC92CA-F78B-4476-B3C4-620E7B61AF9BQ37000735-B1A182AC-10CB-46AB-9E32-36CA715774F3Q37021321-EA5083E6-2DC2-41F7-9748-485B92787C8AQ37211755-A46C50A2-C9FF-4998-B9E2-DB4CAFC52B0DQ37302453-18B390B5-4C2A-43EB-B47D-0B784C5DB476Q37418445-B8602D69-4011-4FF9-9FD6-CACF44BAFE3EQ37603368-E1B9733B-BB9F-4BF0-97FC-B4A232FAA025
P2860
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
@ast
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
@en
type
label
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
@ast
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
@en
prefLabel
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
@ast
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
@en
P1476
Rationale for and use of NMDA receptor antagonists in Parkinson's disease
@en
P2093
David G Standaert
Penelope J Hallett
P304
P356
10.1016/J.PHARMTHERA.2004.04.001
P577
2004-05-01T00:00:00Z